Kaken Pharmaceutical Co Ltd (JP:4521)
:4521
Want to see JP:4521 full AI Analyst Report?
Top Page
Kaken Pharmaceutical Co
(4521)
Select Model
Select Model
Rating:80Outperform
Price Target:
¥4,686.00
▲(26.24% Upside)
Action:Reiterated
Date:09/17/25
Kaken Pharmaceutical Co's strong financial performance and attractive valuation are the most significant factors contributing to its overall score. The company's stable technical indicators further support a positive outlook. However, historical volatility in revenue and cash flow suggests a need for cautious future planning.
Positive Factors
Strong balance sheet
Very low leverage and an ~80% equity ratio give Kaken a stable capital structure and financial flexibility. Low debt reduces refinancing risk and interest burden, enabling sustained funding for R&D, lifecycle management and potential M&A, preserving strategic optionality through policy cycles.
Negative Factors
Recent revenue decline
A material revenue decline (~-19% YoY) weakens top-line momentum and can constrain reinvestment and margin leverage. If stemming from product maturity, NHI price adjustments or volume loss, this decline may represent a multi-quarter structural headwind needing new launches or market expansion to reverse.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Very low leverage and an ~80% equity ratio give Kaken a stable capital structure and financial flexibility. Low debt reduces refinancing risk and interest burden, enabling sustained funding for R&D, lifecycle management and potential M&A, preserving strategic optionality through policy cycles.
Read all positive factors
Kaken Pharmaceutical Co (4521) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥152.18B
Dividend Yield4.16%
Average Volume (3M)164.95K
Price to Earnings (P/E)73.2
Beta (1Y)0.31
Revenue Growth-18.25%
EPS Growth-84.71%
CountryJP
Employees1,135
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)333.12
Shares Outstanding44,139,730
10 Day Avg. Volume176,660
30 Day Avg. Volume164,953
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.12
Price to Sales (P/S)1.82
P/FCF Ratio6.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)44
Revenue Forecast (FY)¥74.16B
Kaken Pharmaceutical Co Business Overview & Revenue Model
Company Description
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychom...
How the Company Makes Money
Kaken Pharmaceutical makes money primarily by selling prescription pharmaceuticals. Revenue is generated when its branded drugs are prescribed by physicians and dispensed to patients, with reimbursement largely occurring under Japan’s national hea...
Kaken Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 94.65B | 94.03B | 72.04B | 72.98B | 76.03B | 74.98B |
| Gross Profit | 58.08B | 58.26B | 38.54B | 39.56B | 41.58B | 40.91B |
| EBITDA | 20.34B | 22.02B | 12.57B | 9.40B | 16.38B | 20.99B |
| Net Income | 12.46B | 13.95B | 8.03B | 5.44B | 9.55B | 13.40B |
Balance Sheet | ||||||
| Total Assets | 176.34B | 190.42B | 171.62B | 166.33B | 165.18B | 165.62B |
| Cash, Cash Equivalents and Short-Term Investments | 55.40B | 70.08B | 65.32B | 74.26B | 74.62B | 77.31B |
| Total Debt | 3.85B | 3.85B | 3.85B | 3.85B | 3.85B | 3.85B |
| Total Liabilities | 28.89B | 37.78B | 27.87B | 29.49B | 26.85B | 29.36B |
| Stockholders Equity | 147.45B | 152.63B | 143.75B | 136.26B | 137.75B | 136.26B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 25.64B | 716.00M | 7.27B | 10.35B | 12.41B |
| Operating Cash Flow | 0.00 | 29.78B | 2.58B | 9.25B | 13.34B | 14.38B |
| Investing Cash Flow | 0.00 | -19.65B | -5.85B | -2.63B | -7.89B | -1.64B |
| Financing Cash Flow | 0.00 | -5.37B | -5.66B | -6.99B | -8.13B | -8.75B |
Kaken Pharmaceutical Co Technical Analysis
Positive
3712.00
Price Trends
4161.67
Positive
4033.93
Positive
3843.44
Positive
Market Momentum
12.13
Positive
50.47
Neutral
46.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4521, the sentiment is Positive. The current price of 3712 is below the 20-day moving average (MA) of 4165.14, below the 50-day MA of 4161.67, and below the 200-day MA of 3843.44, indicating a bullish trend. The MACD of 12.13 indicates Positive momentum. The RSI at 50.47 is Neutral, neither overbought nor oversold. The STOCH value of 46.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4521.
Kaken Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥152.18B | 73.21 | -2.58% | 4.16% | -18.25% | -84.71% | |
73 Outperform | ¥113.49B | 12.60 | 4.81% | 2.34% | 6.18% | 12.52% | |
69 Neutral | ¥73.91B | 27.41 | ― | 3.36% | -2.94% | -62.05% | |
67 Neutral | ¥169.05B | 5.05 | 12.02% | 2.14% | 5.44% | -72.35% | |
59 Neutral | ¥207.15B | 13.89 | ― | 2.28% | 9.06% | -111.21% | |
58 Neutral | ¥179.32B | 14.03 | 6.70% | 2.48% | 10.28% | 20.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4521
Kaken Pharmaceutical Co
4,225.00
710.94
20.23%
JP:4547
Kissei Pharmaceutical Co
4,390.00
734.45
20.09%
JP:4553
Towa Pharmaceutical Co
3,435.00
1,035.75
43.17%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,335.00
424.01
14.57%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,404.00
13.18
0.95%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
2,082.50
345.05
19.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.